Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention ...

The 2025 college baseball season is officially here! With over 4,000 games across ESPN platforms, there will be no shortage ...

Annaly submitted better than expected Q4'24 earnings and the spread picture continues to improve in FY 2025. Read what makes ...

H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

Solvay shows stability with strong fundamentals and a 5.7% dividend yield. Learn why SVYSF stock is a "Buy" under €30 but ...

Wes Hughes reveals his 2025 Second Base Prospect Rankings, analyzing the top emerging talent and their impact in fantasy ...

Kristian Campbell could not be stopped last summer. Drafted by Boston in the fourth round of the 2023 MLB Draft out of Georgia Tech, Campbell was tabbed as a solid contact hitter whose versatility ...

Let's explore one crucial X factor that will prove decisive in the success of each Twins position player this season. We'll ...

Fantasy baseball analyst Scott Pianowski continues his Shuffle Up series with tiered rankings for shortstops and second ...

Billionaire hedge fund manager Bill Ackman revealed on Friday that his activist investment firm has bought up approximately ...

His tenure was marked by scandals, including reports of a toxic workplace culture, regulatory battles and the mishandling of a high-profile sexual harassment case — which led to investor ...